GlassScriptPhysician profile
Kerry R Carder
NPI 1952370405
$4,254.31
in general payments reported to CMS, 2019-2025
29 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $143 · 2021: $148 · 2022: $473 · 2023: $647 · 2024: $1,071 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.23 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $889.80 | 2019-2025 | |
| Pfizer INC. | $551.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $519.44 | 2020-2025 | Dupixent |
| Abbvie INC. | $343.14 | 2019-2025 | Rinvoq |
| Dermavant Sciences, INC. | $311.00 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $247.03 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $185.97 | 2019-2025 | Nemluvio, Aklief |
| Organon LLC | $155.20 | 2025 | Vtama |
| Incyte Corporation | $143.48 | 2021-2025 | Opzelura |
| Encore Dermatology INC. | $129.04 | 2019 | |
| Leo Pharma INC. | $116.78 | 2019-2025 | Adbry |
| Almirall LLC | $99.97 | 2019-2023 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $92.37 | 2022 | |
| Sun Pharmaceutical Industries INC. | $67.75 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.41 | 2024-2025 | Ebglyss, Taltz |
| Lnhc, INC | $44.18 | 2025 | Zelsuvmi |
| Medimetriks Pharmaceuticals, INC. | $36.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.10 | 2025 | Koselugo |
| Krystal Biotech INC | $24.62 | 2023 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.14 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $21.91 | 2023 | Ycanth |
| Mylan Pharmaceuticals INC. | $19.04 | 2019 | |
| Springworks Therapeutics, INC. | $18.64 | 2025 | Gomekli |
| Nobelpharma America, LLC | $16.38 | 2023 | |
| Amgen INC. | $15.21 | 2024 | Otezla |
| Dermira, INC. | $14.35 | 2020 | |
| Vyne Pharmaceuticals INC. | $11.89 | 2020 | |
| Epi Health, LLC | $10.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Carder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.